Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Roche's COVID-19 Test Gets FDA's Emergency Use Authorization

Roche's (RHHBY) Elecsys IL-6 test gets FDA's EUA for identifying patients at high risk of severe inflammatory response.

ALXN : 114.10 (+0.29%)
RHHBY : 43.4850 (-1.04%)
GILD : 77.90 (+4.70%)
LLY : 150.26 (-1.49%)
Alexion to Present at the 41st Annual Global Goldman Sachs Healthcare Conference

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 41st Annual Global Goldman Sachs Healthcare Conference, taking place virtually on Tuesday, June 9th, 2020 at 1:20...

ALXN : 114.10 (+0.29%)
Orphan Drugs Market to Surpass US$ 125,016.1 Mn by 2025, Pfizer's Strong Distribution Network to Enable it Establish a Stronghold Worldwide, states Fortune Business Insights

The rising prevalence for chronic diseases is a major factor expected to drive the global orphan drugs market during the forecast period. Fortune Business Insights in a recent report, titled "Orphan Drugs...

ALXN : 114.10 (+0.29%)
AZN : 54.04 (-1.75%)
BAYRY : 17.8500 (-2.99%)
BMY : 60.68 (+0.78%)
DSNKY : 84.3100 (-1.19%)
GSK : 41.81 (-0.74%)
NVO : 64.49 (-0.34%)
Gilead Down on Mixed Results From Coronavirus Drug Remdesivir

Gilead's (GILD) shares decline on mixed results from a late-stage study on coronavirus drug.

ALXN : 114.10 (+0.29%)
RHHBY : 43.4850 (-1.04%)
GILD : 77.90 (+4.70%)
INCY : 94.96 (-3.92%)
Alexion Pharmaceuticals (ALXN) Stock Sinks As Market Gains: What You Should Know

Alexion Pharmaceuticals (ALXN) closed at $118.92 in the latest trading session, marking a -0.82% move from the prior day.

ALXN : 114.10 (+0.29%)
Roche Starts Study on Actemra with Gilead's Drug for Coronavirus

Roche (RHHBY) commences a phase III study on Actemra with Gilead's remdesivir in hospitalized patients with severe COVID-19 pneumonia.

ALXN : 114.10 (+0.29%)
RHHBY : 43.4850 (-1.04%)
GILD : 77.90 (+4.70%)
INCY : 94.96 (-3.92%)
Alexion (ALXN) Catches Eye: Stock Jumps 7.8%

Alexion (ALXN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

ALXN : 114.10 (+0.29%)
AKCA : 14.99 (+0.81%)
China Concerns Spark Late-Day Selloff

China Concerns Spark Late-Day Selloff

GPK : 14.66 (-1.48%)
PINS : 21.48 (+0.19%)
INMD : 33.78 (+3.30%)
NBIX : 120.37 (+1.13%)
ADBE : 384.54 (-1.38%)
ATEYY : 53.4100 (-0.57%)
NTRS : 87.14 (+2.35%)
AKAM : 102.80 (-0.20%)
TCEHY : 55.6000 (-1.23%)
ALXN : 114.10 (+0.29%)
GES : 12.15 (+3.14%)
PLT : 13.91 (-0.71%)
RDWR : 23.66 (-1.91%)
PS : 20.80 (+0.19%)
FIZZ : 56.80 (-0.89%)
TTD : 343.82 (-3.14%)
UNFI : 20.84 (+1.31%)
PFPT : 113.85 (-2.40%)
SDOW : 24.20 (+0.29%)
Thinking about trading stocks or options in Toll Brothers, Alexion Pharmaceuticals, SeaWorld Entertainment, Southwest Airlines, or Microchip Technology?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TOL, ALXN, SEAS, LUV, and MCHP.

ALXN : 114.10 (+0.29%)
MCHP : 106.98 (-1.66%)
SEAS : 19.74 (+6.30%)
LUV : 39.09 (+7.33%)
TOL : 34.89 (-2.54%)
iCo Therapeutics Announces 2019 Year End Financial Results

Vancouver, British Columbia--(Newsfile Corp. - May 19, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the year ended December 31, 2019....

ALXN : 114.10 (+0.29%)
ICO.VN : 0.050 (+11.11%)
ICOTF : 0.0333 (+5.38%)
Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data

Sarepta (SRPT) investors cheer the announcement of Pfizer's early-stage gene therapy study data, which seems to trail Sarepta's gene therapy candidate, SRP-9001's performance.

ALXN : 114.10 (+0.29%)
RHHBY : 43.4850 (-1.04%)
PFE : 36.02 (-0.39%)
SRPT : 146.18 (-1.92%)
UnitedHealthcare Ties Up to Improve Eye Health of Members

UnitedHealth Group's (UNH) UnitedHealthcare business collaborates with GlassesUSA.com for providing improved eye care to its eligible members.

UNH : 297.35 (-2.62%)
ALXN : 114.10 (+0.29%)
HUM : 392.89 (-0.21%)
ENSG : 44.69 (-0.82%)
Alexion Announces Upcoming Data Presentations at the Virtual 25th Congress of the European Hematology Association

--- Data from five abstracts demonstrate Alexion's continued commitment to advancing the understanding of PNH with ongoing real-world studies and emerging clinical data -

ALXN : 114.10 (+0.29%)
Sanofi's Blood Disorder Candidate Gets FDA's Priority Review

The FDA grants priority review to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD).

BIIB : 300.25 (-0.78%)
ALXN : 114.10 (+0.29%)
SNY : 50.05 (+0.95%)
GBT : 65.64 (-1.80%)
MEDNAX Affiliate Ties Up With CDI to Improve Patient Care

MEDNAX's (MD) affiliate Jefferson Radiology collaborates with CDI for providing enhanced healthcare services to the Springfield community.

ALXN : 114.10 (+0.29%)
HUM : 392.89 (-0.21%)
MD : 16.94 (+0.24%)
ENSG : 44.69 (-0.82%)
Look for Shares of Alexion Pharm to Potentially Pullback after Yesterday's 2.97% Rise

Alexion Pharm (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $102.69 to a high of $105.09. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of...

ALXN : 114.10 (+0.29%)
Monoclonal Antibody Therapy Market to Rise at 14.0% CAGR till 2027; Growing Investment in Product R&D will Create Several Opportunities for Market Growth, says Fortune Business Insights(TM)

The global monoclonal antibodies therapy market size is projected to reach USD 350.10 billion by the end of 2027. The increasing prevalence of severe diseases such as cancer will create several opportunities...

ALXN : 114.10 (+0.29%)
AMGN : 219.80 (-0.54%)
BMY : 60.68 (+0.78%)
DSNKY : 84.3100 (-1.19%)
MRK : 81.52 (-0.66%)
NVS : 85.47 (-0.27%)
Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

, May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the...

PTLA : 17.92 (-0.06%)
ALXN : 114.10 (+0.29%)
Are Biotech ETFs in Trouble as Coronavirus Dims Guidance?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q1 earnings releases amid the coronavirus crisis.

BIIB : 300.25 (-0.78%)
ALXN : 114.10 (+0.29%)
GILD : 77.90 (+4.70%)
AMGN : 219.80 (-0.54%)
IBB : 132.01 (-0.48%)
XBI : 103.12 (-0.79%)
BBH : 158.49 (-0.30%)
Is Alexion Pharmaceuticals (ALXN) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

ALXN : 114.10 (+0.29%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -1.80 , SEDG -7.36 , THC +0.12 , TER +1.03 , LITE -1.46
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar